ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 570

A Molecular Timeline for Preclinical RA Pathogenesis Defined By Dysregulated PTPN22, Hypercitrullination, and Aberrant Cytokine/Metabolic Profiles in PBMC of at-Risk Individuals

Hui-Hsin Chang1, Nishant Dwivedi2, Bo Sun2, Deepak A. Rao3, Jeffrey A. Sparks3, Jennifer Kinslow4, Yuko Okamoto4, Kevin D. Deane5, M. Kristen Demoruelle6, Jill M. Norris7, Elizabeth Karlson2, V. Michael Holers8 and I-Cheng Ho1, 1Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 3Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 4University of Colorado School of Medicine, Aurora, CO, 5Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 6Rheumatology, University of Colorado School of Medicine, Aurora, CO, 7Epidemiology, Colorado School of Public Health, Aurora, CO, 8Rheumatology Division, University of Colorado School of Medicine, Aurora, CO

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: citrullination and rheumatoid arthritis, PAD, pathogenesis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: One unique feature of RA is the presence of ACPA. PTPN22 is a phosphatase that also acts to suppress citrullination independently of its phosphatase activity by inhibiting the function of peptidyl arginine deiminases (PADs). A C-to-T single nucleotide polymorphism, converting an arginine (R620) of PTPN22 to a tryptophan (W620), renders PTPN22 unable to suppress PADs and is associated with higher risk of RA and hypercitrullination in PBMC. Th cells of RA patients are prone to differentiation into Th17 cells and display hypoglycolysis, hyperproliferation, and excessive reductive stress due to abnormal expression of PFKFB3, ATM, and G6PD. We postulate that these abnormal features and hypercitrullination predate the onset of clinical symptoms of RA and can be attributed to attenuated phosphatase and/or non-phosphatase activities of PTPN22.

Methods: PBMC were collected from healthy at-risk individuals (ARIs), including RA first-degree relatives and/or ACPA+ individuals, and healthy ACPA- control individuals. The PBMC were stimulated with anti-CD3. Intracellular staining, western blotting, and real time PCR were used to quantify the level of citrullinated proteins and the expression of various genes. The levels of cytokines and lactate in supernatant were measured with ELISA and a colorimetric assay.  PBMC were also transfected with plasmid vectors expressing PTPN22 or PADs to examine the impact of these proteins on the phenotype of PBMC.

Results: Regardless of the ACPA status, a high level of citrullinated histone H3 (cit-H3) was detected in ARIs but not in the control populations. T cells were the major source of cit-H3 in ARI PBMC. Despite a normal level of G6PD, ARI PBMC expressed more IL-2 and IL-17, but less IL-4, ATM and PFKFB3, and were hypoglycolytic. These abnormal features and hypercitrullination correlated with impaired anti-CD3-mediated induction of PTPN22 and were rectified by exogenous PTPN22. A phosphatase-dead PTPN22 was still able to normalize the level of cit-H3, IL-4 and IL-17 but not IL-2, ATM, or PFKFB3. In contrast, W620-PTPN22 normalized the expression of IL-2, ATM, and PFKFB3, but not IL-4 or IL-17. Furthermore, forced expression of PAD2 or PAD4 in control PBMC induced hypercitrullination and reduced the expression of IL-4, whereas only PAD2 was able to enhance the expression of IL-17.

Conclusion: Our data depict a molecular timeline of preclinical RA (Figure 1): impaired induction of PTPN22 leading to attenuated phosphatase activity and PADs-mediated hypercitrullination. The attenuated phosphatase activity results in aberrant expression of IL-2, ATM, and PFKFB3, whereas PAD2- or PAD4-mediated hypercitrullination inhibits the expression of Th2 cytokine. However, only PAD2-mediated hypercitrullination can augment the expression of Th17 cytokines. All of these events take place with or without the development of ACPA and abnormal expression of G6PD.


Disclosure: H. H. Chang, None; N. Dwivedi, None; B. Sun, None; D. A. Rao, None; J. A. Sparks, None; J. Kinslow, None; Y. Okamoto, None; K. D. Deane, None; M. K. Demoruelle, None; J. M. Norris, None; E. Karlson, None; V. M. Holers, Patents, 9; I. C. Ho, None.

To cite this abstract in AMA style:

Chang HH, Dwivedi N, Sun B, Rao DA, Sparks JA, Kinslow J, Okamoto Y, Deane KD, Demoruelle MK, Norris JM, Karlson E, Holers VM, Ho IC. A Molecular Timeline for Preclinical RA Pathogenesis Defined By Dysregulated PTPN22, Hypercitrullination, and Aberrant Cytokine/Metabolic Profiles in PBMC of at-Risk Individuals [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/a-molecular-timeline-for-preclinical-ra-pathogenesis-defined-by-dysregulated-ptpn22-hypercitrullination-and-aberrant-cytokinemetabolic-profiles-in-pbmc-of-at-risk-individuals/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-molecular-timeline-for-preclinical-ra-pathogenesis-defined-by-dysregulated-ptpn22-hypercitrullination-and-aberrant-cytokinemetabolic-profiles-in-pbmc-of-at-risk-individuals/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology